Drug-resistant epilepsy pipeline

Feb 09, 2026

Summary Drug-resistant epilepsy affects 20-40% of epilepsy patients in the US, rising to 30-40% in adults versus 7-20% in children, with similar rates (over 25%) in Europe; about one-quarter of newly diagnosed cases progress to DRE. Vagus Nerve Stimulation (VNS Therapy by LivaNova) is FDA-approved for drug-r...

Mar 22, 2021

Which Pharma Companies are Transforming the Drug-Resistant Epilepsy Market Landscape? In the United States, more than 2.5 million people are living with Epilepsy, out of which approximately 1 million continue to experience seizures despite adequate treatment with antiseizure drugs. Known as Drug-resistant epilep...